Details of the Drug Combination

General Information of Drug Combination (ID: DC1IN8D)

Drug Combination Name
Linezolid Cefiderocol
Indication
Disease Entry Status REF
Healthcare-associated Pneumonia (HCAP) Phase 3 [1]
Component Drugs Linezolid   DMGFPU2 Cefiderocol   DMJSMDL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Linezolid
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Skin infection 1F28-1G0Z Investigative [2]
Linezolid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA) TTLFGBV NOUNIPROTAC Binder [7]
------------------------------------------------------------------------------------
Linezolid Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Decreases Activity [8]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Decreases Activity [8]
------------------------------------------------------------------------------------
Indication(s) of Cefiderocol
Disease Entry ICD 11 Status REF
Hospital-acquired pneumonia CA40.Z Approved [5]
Urinary tract infection GC08 Approved [5]
Ventilator-associated pneumonia PK81.0 Approved [5]
Healthcare-associated pneumonia CA00-CA40 Phase 3 [6]

References

1 ClinicalTrials.gov (NCT03032380) Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
2 Linezolid FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 200222.
4 Therapeutic and Triage Strategies for 2019 Novel Coronavirus Disease in Fever Clinics. Lancet Respir Med. 2020 Mar;8(3):e11-e12.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 ClinicalTrials.gov (NCT02714595) Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens (CREDIBLE - CR). U.S. National Institutes of Health.
7 Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
8 Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29.